D-0673-2026 Class II Ongoing

Recalled by Reliance Life Sciences Private Limited — Navi Mumbai, N/A

FDA drug recall D-0673-2026 was initiated by Reliance Life Sciences Private Limited on Jun 24, 2026 and is designated Class II. Reason for recall: Lack of Sterility Assurance The recall status is ongoing. Affected quantity: 11,400 vials.

Recall details

Product Type
Drugs
Report Date
Jul 15, 2026
Initiation Date
Jun 24, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,400 vials

Product description

Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01

Reason for recall

Lack of Sterility Assurance

Distribution pattern

Nationwide in the USA

Code information

Lot, expiry: RBIH0125A Jan 31, 2028; RBIH0225A Feb 29, 2028; RBIH0325A Feb 29, 2028; RBIH0525A Mar 31, 2028

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0673-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0673-2026. Report a data issue: hello@regdatalab.com.